Examples of using Major bleeding in English and their translations into Croatian
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
Major bleeding during treatment occurred in 1(0.1%)
Major bleeding was defined in the PURSUIT trial as either an intracranial haemorrhage
Velika krvarenja definirana su u PURSUIT ispitivanju ili kao intrakranijalno Major bleeding was observed in 3.4% of the patients in the fondaparinux group and in 2.4% of the dalteparin group.
Veliko krvarenje zabilježeno je u 3,4% bolesnika u skupini koja je dobivala fondaparinuks te u 2,4% bolesnika u skupini koja je dobivala dalteparin.For the primary safety outcome(major bleeding events) there was a non-significant numerically higher incidence rate for patients treated with rivaroxaban 20 mg once daily compared to placebo.
Kod primarnog ishoda sigurnosti(veća krvarenja) postojala je neznačajna brojčano viša stopa incidencija kod bolesnika liječenih rivaroksabanom od 20 mg jednom na dan u usporedbi s placebom.Minor or major bleeding,(for example,
Manja ili velika krvarenja(npr. krv u mokraći,total PLATO Major bleeding did not differ between ticagrelor
ukupno veliko krvarenje u studiji PLATO se nije razlikovalo između tikagreloraMajor bleeding occurred in 35(0.4%)
Veće krvarenje pojavilo se u 35(0,4%)The incidence rates for the principal safety outcome(non-CABG TIMI major bleeding events) were higher in patients treated with Xarelto than in patients who received placebo see Table 5.
Stope incidencije glavnog ishoda sigurnosti(ne-CABG TIMI veća krvarenja) bile su više u bolesnika liječenih lijekom Xarelto nego u bolesnika koji su primali placebo vidjeti tablicu 5.clopidogrel has been shown to increase major bleeding.
kombinacija ASK i klopidogrela pojačava velika krvarenja.Acquired haemophilia must be promptly recognised to minimise the time the patient is at risk of bleeding and avoid major bleeding.
Stečenu hemofiliju potrebno je hitno prepoznati kako bi se minimaliziralo vrijeme u kojem je bolesnik u riziku od The main safety endpoint, major bleeding, showed comparable rates for patients treated with rivaroxaban 10 mg compared to enoxaparin 40 mg.
Glavni ishod sigurnosti, veće krvarenje, pokazao je usporedivu stopu u bolesnika koji su uzimali rivaroksaban 10 mg s onom u bolesnika koji su uzimali enoksaparin 40 mg.Minor bleeding occurred very commonly(1/10) and major bleeding occurred commonly1/100 and< 1/10.
Mala clinically relevant non-major bleeding events) as well as the secondary safety outcome(major bleeding events) were similar for both treatment groups.
klinički značajna manja with central outcome adjudication including recurrent VTE, major bleeding and death has been conducted.
otvoreno ispitivanje kohorti(XALIA), s centralnom ocjenom ishoda koji su uključivali ponavljajući VTE, veće krvarenje i smrt.Minor bleeding occurred very commonly(1/10) and major bleeding occurred commonly1/100 and< 1/10.
Mala Thrombotic(9/110, 8.2%) and major bleeding events(2/110, 1.8%) were observed in the study.
U ispitivanju su zabilježeni trombotički događaji(9/110; 8,2%) i velika krvarenja 2/110: 1, 8.PLATO total Major bleeding, TIMI Major bleeding, or TIMI Minor bleeding Table 2.
PLATO ukupna velika krvarenja, TIMI velika krvarenja, ili TIMI manja Major bleeding rates in clinical trials of bivalirudin 30 day endpoints for intent-to- treat populations.
Stope velikih krvarenja u 30-dnevnim ishodima kliničkih ispitivanjima s bivalirudinom u populaciji s namjerom liječenja.Table 7: Number of Major Bleeding Events by creatinine clearance category in ENGAGE AF- TIMI 48, Safety Analysis On-Treatmenta.
Tablica 7: Broj velikih krvarenja prema kategoriji klirensa kreatinina u ispitivanju ENGAGE AF-TIMI 48, analiza sigurnosti tijekom liječenjaa.In the study, the incidence in major bleeding for both apixaban doses was not statistically different from placebo.
U ispitivanju, incidencija u značajnom krvarenju obje doze apiksabana nije se statistički razlikovala od placeba.
